Navigation Links
Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial
Date:11/5/2011

and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.  Follow us on www.twitter.com/amgen.

Forward-Looking Statements

This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Nov. 5, 2011 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be gu
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
2. Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
3. Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
4. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
5. XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
6. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
7. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
8. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
9. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
10. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
11. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 3, 2015   ... 240 patients respectively Publications in peer reviewed ... Clinical Gastroenterology highlight diagnostic value of confocal laser ... China and across Asia ... (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal ...
(Date:3/3/2015)... and Markets ( http://www.researchandmarkets.com/research/x5lz9r/global_poc ) has announced ... 2015-2019" report to their offering. , ... to grow at a CAGR of 8.47 percent over ... IVD devices and tools used for diagnosing diseases in ... these devices helps in the rapid diagnosis of the ...
(Date:3/3/2015)... WAYNE, N.J. , March 3, 2015 ... USA announced today a new, integrated ... new portable solution is now available with a larger ... integrated console mounted system offers a larger viewing area ... console now provides additional space for accessories and storage, ...
Breaking Medicine Technology:Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 3Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 4Global POC Diagnostics Market 2015-2019 with Abbott Labs, Alere, Bayer Healthcare, Danaher, F. Hoffmann-La Roche & Johnson & Johnson Dominating 2Konica Minolta Medical Imaging and Shimadzu Medical Systems USA Introduce MobileArt Evolution EFX AeroDR-i with 17" Touch Monitor to Simplify Operation 2Konica Minolta Medical Imaging and Shimadzu Medical Systems USA Introduce MobileArt Evolution EFX AeroDR-i with 17" Touch Monitor to Simplify Operation 3
... Safety and Reduce Health Care CostsBETHESDA, Md., May 7 ... pilot program, contributing data on adverse events associated with ... will be possible to identify best practices that can ... overall costs to the health care system.This pilot hemovigilance ...
... Society Annual Meeting-BALTIMORE, May 7 Arcion Therapeutics, ... that develops pain therapies, today announced the presentation ... significantly reduced pain caused by diabetic neuropathy in ... presented in a poster session on May 8th ...
Cached Medicine Technology:National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 2National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 3Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy 2Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy 3
(Date:3/3/2015)... Dan E. Chambers, an experienced Los Angeles criminal ... recently spoke on the radio to give his insights into ... Independent Journal Review radio show “The Right Mics” chose Chambers ... and now as a criminal defense attorney would provide him ... and sentencing of this high-profile case. , During the ...
(Date:3/3/2015)... The report “Alopecia – Pipeline Review, H1 2015? ... Alopecia is the loss of hair. Alopecia areata and ... Causes for alopecia include aging, genetics, illness, chemotherapy, malnutrition ... pattern hair loss, female diffuse hair loss, hairs easily ... focal or diffuse and by the presence or absence ...
(Date:3/3/2015)... Houston, TX (PRWEB) March 03, 2015 ... sponsored by the National Sleep Foundation. The event brings ... the world over. , According to the ... ongoing sleep problems of one form or another. Too ... a greater risk of physical illness and depression, and ...
(Date:3/3/2015)... The combinatorial, multi-gene GeneSight test has ... for patients with depression, and their use of ... genes that comprise the test, according to a ... and Assurex Health, and published online by The ... of the GeneSight Psychotropic test is based on ...
(Date:3/3/2015)... 03, 2015 The North ... to grow from $1,224.6 million to $1,694.6 ... 2014 and 2019. , Browse through the ... market for an analysis of industry trends ... tables and figures., http://www.micromarketmonitor.com/market/north-america-application-delivery-network-adn-7381582251.html , ...
Breaking Medicine News(10 mins):Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 2Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 2Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 2Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 4Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 5Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 6Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 2Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 3
... 21 countries, reserachers have found that blood pressure levels across ... not go down in all of the populations, but it ... led the World Health Organization MONICA study conducted between 1980s ... did appear to have a cross- population effect. Most importantly, ...
... overseas-trained doctor, Farid Zaer, who has registered himself as ... Queensland, to continue his medical practice.// The doctor has ... accused for wrong diagnosis involving nearly 208 patients. ... as a GP, without any restriction or supervision. Under ...
... African American children deteriorate as they progress through puberty, ... of Alberta//. The levels of insulin, however, remain unchanged ... phase of growth plays a crucial role in determining ... 7-year, Alabama based study was conducted by Dr. Geoff ...
... to tackle the global threat from bird flu, it ... is felt that// it may provide the best help ... up such a system has been published in the ... through co-ordination between such international labs can warn the ...
... pregnancy can reduce the incidence of pregnancy complications, ... by American Journal of Obstetrics and Gynecology. ... blood pressure and proteinuria (high levels of protein ... and legs is usually seen. If left unattended, ...
... In an attempt to spread awareness about AIDS/HIV, the ... the State organized a health awareness program// ('One step ... targeted specifically at barbers. ,The local barbers, ... rally. A special AIDS/HIV awareness session was conducted at ...
Cached Medicine News:Health News:Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered 2Health News:African American Children More Pone to Develop Diabetes 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: